Networks of Centres of Excellence of Canada
Government of Canada

Common menu bar links

Institute for Research in Immunology and Cancer - Commercialization of Research - IRICoR

$25 million for 2018-24
About   |   News

Institute for Research in Immunology and Cancer (IRIC)
Université de Montréal, Montréal, Quebec

Chief Executive Officer
Nadine Beauger Nadine Beauger

Vice-President, Business Development
Steven Klein Steven Klein

Board Chair
Jean-François Leprince  Jean-François Leprince

Leading the way to next-generation cancer therapies

The opportunity

Cancer remains the number one killer in most industrialized countries, costing Canada $14 billion yearly. 1 in 4 Canadians will die from the disease, and nearly 1 in 2 Canadians will be diagnosed with cancer in their lifetime. The Canadian health care system faces increasing demand for novel, more targeted and more effective cancer treatment options. Our economy is putting greater emphasis on the emergence of personalized medicine treatments and artificial intelligence to accelerate drug discovery/development (DD). Canada has an opportunity to respond swiftly and deliver new innovative cancer therapies for the future.

How IRICoR is seizing the opportunity

As a not-for-profit organization, founded in 2008 by the Université de Montréal, IRICoR was created to fill a gap in Canada’s innovation landscape by supporting academic research projects in oncology throughout the DD process toward commercialization.

With the business and scientific experience it has accumulated to date, its extensive network of renowned Canadian and international collaborators, and its privileged access to Canada’s premier DD chain expertise and infrastructure at Université de Montréal’s Institute for Research in Immunology and Cancer, IRICoR can respond rapidly and effectively to major changes in the life sciences sector. The Centre provides a turnkey solution for academics and small biotechs across Canada and abroad to transform research results into novel therapies. Through partnerships with pharma companies and creation of spin-off companies, IRICoR maximizes the economic impact of each innovative project.

Among the expected results

  • IRICoR will scale up its activities to accelerate the discovery of more innovative therapies and their transfer to the clinic for the benefit of patients. The Centre will identify a growing number of pan-Canadian and international projects that would benefit from its turnkey service and its expertise in DD, IP and commercialization support, adding value by creating spin-off companies and starting clinical trials. IRICoR will also attract strong business leaders and contribute to developing a new generation of life science entrepreneurs through its new entrepreneurship program.
  • The Centre will also offer partners new high-tech equipment and DD capabilities, in particular its new Centre for Advanced Proteomics and Chemogenomics Analyses (CAPCA) and its artificial intelligence research hub at Université de Montréal’s Institute for Data Valorization (IVADO) and the Montreal Institute for Learning Algorithms (MILA).
  • The Centre’s innovative business model will foster strong collaborations with key stakeholders from academia, industry and the life science sector in general, attracting significant Canadian and foreign investments to revitalize the industry interest in Canada.

Connect with IRICoR


February 1, 2019
November 5, 2018